Acclarent Inc., a Menlo Park, Calif.-based developer of surgical devices for treating ear, nose and throat ailments, has filed for an $86.25 million IPO. It plans to trade on either the Nasdaq or NYSE Arca, with JPMorgan and Piper Jaffray serving as co-lead underwriters.
The company has raised around $63 million in VC funding, from firms like New Enterprise Associates (44.2% pre-IPO stake) and Versant Ventures (15.3%). Meritech Capital Partners (8.3%) and Delphi Ventures. www.acclarent.com